Cox-2 Selective Inhibitors and Bone

  • S. B. Goodman
    Department of Orthopaedic Surgery and Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, CA, USA
  • T. Ma
    Department of Orthopaedic Surgery and Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, CA, USA
  • M. Genovese
    Department of Orthopaedic Surgery and Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, CA, USA
  • R. Lane Smith
    Department of Orthopaedic Surgery and Division of Immunology and Rheumatology, Stanford University Medical Center, Stanford, CA, USA

説明

<jats:p> Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed medications for relief of pain and inflammation. Recent animal studies using models of fracture healing and bone ingrowth suggest that NSAIDs (both non-selective NSAIDs and selective COX-2 inhibitors) adversely affect these bone-related processes. The dose and time-relationships of these medications and their resulting effects on bone have not yet been fully elucidated. Furthermore, whether COX-2 inhibitors and non-selective NSAIDs lead to clinically relevant adverse effects on bone healing in humans is unknown. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ